ESR1 and prostate carcinoma: Surprisingly, DES, an ER agonist and an agent used effectively for androgen deprivation therapy of prostate cancer in the clinic, did not display any inhibitory effect on DHT-induced LAPC-4 prostate cancer cell proliferation, whereas it completely blocked DHT-induced cell growth in HAECs at low nanomolar concentrations.